Some federal lawmakers and governors have been lobbying FDA to ease the way for the production and sale of generic insulin, which analysts say would reduce the cost of diabetes treatment by 25%, the New York Times reports. Generic insulin could mean spending reductions for Medicaid programs -- which spent $500 million on the treatment in 2005 -- as well as for people with diabetes. [click link for full article]
More...
Linear Mode
